title: A Review of Experimental and Off-Label Therapies for Clostridium difficile Infection.
abstract: In spite of increased awareness and the efforts taken to optimize Clostridium difficile infection (CDI) management, with the limited number of currently available antibiotics for C. difficile the halt of this increasing epidemic remains out of reach. There are, however, close to 80 alternative treatment methods with controversial anti-clostridial efficacy or in experimental phase today. Indeed, some of these therapies are expected to become acknowledged members of the recommended anti-CDI arsenal within the next few years. None of these alternative treatment methods can respond in itself to all the major challenges of CDI management, which are primary prophylaxis in the susceptible population, clinical cure of severe cases, prevention of recurrences, and forestallment of asymptomatic C. difficile carriage and in-hospital spread. Yet, the greater the variety of treatment choices on hand, the better combination strategies can be developed to reach these goals in the future. The aim of this article is to provide a comprehensive summary of these experimental and currently off-label therapeutic options.
authors.affiliation: Department of Infectious Diseases, Hospital Clínic of Barcelona, Barcelona, Spain. cfeher@clinic.ub.es.
authors.forename: Csaba
authors.identifier: http://orcid.org/0000-0001-6679-493X
authors.initials: C
authors.lastname: Fehér
authors.affiliation: Department of Infectious Diseases, Hospital Clínic of Barcelona, Barcelona, Spain.|August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.|University of Barcelona, Barcelona, Spain.
authors.forename: Alex
authors.initials: A
authors.lastname: Soriano
authors.affiliation: Department of Infectious Diseases, Hospital Clínic of Barcelona, Barcelona, Spain.|August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
authors.forename: Josep
authors.initials: J
authors.lastname: Mensa
keywords: Clinical development pipeline; Clostridium difficile infection (CDI); Controversial therapies; Experimental therapies